Experience with Rezoklastin FS in the correction of disorders in patients with postmenopausal osteoporosis

Eliseeva L.N.; Reznikova L.B.; Tikhomirova N.Iu.

doi:https://doi.org/

Eliseeva L.N.

Kubanskiĭ gosudarstvennyĭ meditsinskiĭ universitet

Reznikova L.B.

Meditsinskiĭ tsentr "Garmoniia", Krasnodar

Tikhomirova N.Iu.

Kubanskiĭ gosudarstvennyĭ meditsinskiĭ universitet

Experience with Rezoklastin FS in the correction of disorders in patients with postmenopausal osteoporosis

Authors:

Eliseeva L.N., Reznikova L.B., Tikhomirova N.Iu.

More about the authors

Journal: Russian Bulletin of Obstetrician-Gynecologist. 2013;13(3): 80‑82

Read: 3408 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Eliseeva LN, Reznikova LB, Tikhomirova NIu. Experience with Rezoklastin FS in the correction of disorders in patients with postmenopausal osteoporosis. Russian Bulletin of Obstetrician-Gynecologist. 2013;13(3):80‑82. (In Russ.)

Подписка 2026 Российский вестник акушера-гинеколога (Russian Bulletin of Obstetrician-Gynecologist)

Использование инфографики авторами научных работ

References:

Osteoporoz. Diagnostika, profilaktika i lechenie. Pod red. O.M. Lesnyak, L.I. Benevalenskoi. M: GEOTAR-Media 2009; 272.
Black D.M., Delmas P.D., Eastell R. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007; 356: 1809-1822.
Chaki O., Yoshikata I., Kikuchi R. The predictive value of biochemical markers of bone turnover for bone mineral density in postmenopausal Japanese women. J Bone Miner Res 2000; 15: 8: 1537-1544.
Christenson R.H. Biochemical markers of bone metabolism: an overview. Clin Biochem 1997; 30: 8: 573-593.
Garcia-Perez M.A., Moreno-Mercer J., Tarin J.J., Cano A. Relationship between PTH, sex steroid and bone turnover marker measurements and bone density in recently postmenopausal women. Maturitas 2003; 45: 67-74.
Lönnroos E., Kautiainen H., Karppi P., Hartikainen S., Kiviranta I., Sulkava R. Incidence of second hip fractures: a population-based study. Osteopor Int 2007; 18: 1279-1285.
Lyles K.W., Colón-Emeric C.S., Magaziner J.S. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007; 357; DOI: 10.1056/NEJMoa074941
McClung M.R., Geusens P., Miller P.D. Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 2001; 344: 333-340.
Ravn P., Thompson D.E., Ross P.D., Christiansen C. Biochemical markers for prediction of 4-year response in bone mass during bisphosphanate treatment for prevention of postmenopausal osteoporosis. Bone 2003; 33: 1: 150-158.